Coreline Soft AI Lung Analysis Confirms Prognosis Prediction for Interstitial Lung Disease

Asan Medical Center Research Team Publishes Findings in CHEST

Coreline Soft's chest artificial intelligence (AI) quantitative analysis technology has demonstrated the potential to serve as a digital biomarker capable of predicting disease progression and survival prognosis in the field of interstitial lung disease (ILD).

Coreline Soft thoracic AI platform Aview operating screen. Coreline Soft

On May 28, a research team from the Department of Radiology and the Department of Pulmonology at Asan Medical Center in Seoul announced that the fibrosis score (FS), calculated using Coreline Soft's chest AI platform 'AVIEW', was shown to be a significant indicator for predicting disease progression and survival prognosis in patients with ILD. The findings were recently published in the international journal 'Chest'.

The FS is an index produced by AI through quantitative analysis of reticular and honeycomb patterns in chest CT images. By quantifying imaging patterns indicative of pulmonary fibrosis progression, FS allows for a quantitative assessment of structural changes that are difficult to detect with conventional visual interpretation or pulmonary function tests (PFT) alone.

The research team explained that, over the course of one year of follow-up, changes in FS showed higher statistical significance in assessing disease progression and prognosis than the decline in forced vital capacity (FVC), which is the current clinical standard indicator. They emphasized that this study demonstrates how AI-based CT quantitative analysis technology can be utilized not only as an aid for image interpretation, but also for long-term follow-up and evaluation of treatment response in lung diseases.

Interstitial lung disease is a group of intractable diseases characterized by inflammation and fibrosis of the lung interstitium. Due to the nature of the disease, early diagnosis and long-term follow-up are important, but as there are limited therapeutics that fundamentally reverse fibrosis, there is a significant unmet need for predicting disease progression and evaluating treatment response in this field.

Coreline Soft plans to use this study as an opportunity to expand the application of its AI quantitative analysis technology beyond the fields of lung cancer and cardiovascular disease to include intractable lung diseases, while also broadening the potential for collaboration with global pharmaceutical and biotechnology companies.

This content was produced with the assistance of AI translation services.